Financials data is unavailable for this security.
View more
Year on year Recursion Pharmaceuticals Inc had net income fall 36.99% from a loss of 239.48m to a larger loss of 328.07m despite a 11.88% increase in revenues from 39.84m to 44.58m. An increase in the selling, general and administrative costs as a percentage of sales from 240.07% to 300.58% was a component in the falling net income despite rising revenues.
| Gross margin | 35.07% |
|---|---|
| Net profit margin | -579.51% |
| Operating margin | -604.70% |
| Return on assets | -55.66% |
|---|---|
| Return on equity | -78.49% |
| Return on investment | -65.45% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Recursion Pharmaceuticals Inc fell by 157.69m. Cash Flow from Financing totalled 140.13m or 314.38% of revenues. In addition the company used 287.78m for operations while cash used for investing totalled 10.23m.
| Cash flow per share | -1.39 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1.83 |
|---|---|
| Tangible book value per share | 1.53 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.35 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.0548 |
|---|---|
| Total debt/total capital | 0.0519 |
More ▼
